These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17373058)

  • 21. Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.
    Wood E; Tyndall MW; Spittal PM; Li K; Anis AH; Hogg RS; Montaner JS; O'Shaughnessy MV; Schechter MT
    CMAJ; 2003 Jan; 168(2):165-9. PubMed ID: 12538544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives.
    Murty M
    Can J Physiol Pharmacol; 2007 Sep; 85(9):952-5. PubMed ID: 18066142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving health and social care relationships for harm reduction.
    Allman D; Myers T; Schellenberg J; Strike C; Cockerill R; Cavalieri W
    Int J Drug Policy; 2007 May; 18(3):194-203. PubMed ID: 17689366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug treatment courts in Canada: an evidence-based review.
    Werb D; Elliott R; Fischer B; Wood E; Montaner J; Kerr T
    HIV AIDS Policy Law Rev; 2007 Dec; 12(2-3):12-7. PubMed ID: 18459192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescription drug benefits and Canada's uninsured.
    Dewa CS; Hoch JS; Steele L
    Int J Law Psychiatry; 2005; 28(5):496-513. PubMed ID: 16125777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economy, costs and funding: key issues for Canada's health care system.
    Rea PA; Tregunna K
    Leadersh Health Serv; 1992; 1(4):33-6. PubMed ID: 10123136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canada's National Advisory Committee on Immunization (NACI): evidence-based decision-making on vaccines and immunization.
    Ismail SJ; Langley JM; Harris TM; Warshawsky BF; Desai S; FarhangMehr M
    Vaccine; 2010 Apr; 28 Suppl 1():A58-63. PubMed ID: 20412999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Australian governments' spending on preventing and responding to drug abuse should target the main sources of drug-related harm and the most cost-effective interventions.
    McDonald D
    Drug Alcohol Rev; 2011 Jan; 30(1):96-100. PubMed ID: 21219503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health Canada's policy on extra-label drug use in food-producing animals in Canada.
    Grignon-Boutet R; Ireland MJ; Adewoye L; Mehrotra M; Russell S; Alexander I
    Can Vet J; 2008 Jul; 49(7):689-93. PubMed ID: 18827846
    [No Abstract]   [Full Text] [Related]  

  • 31. Canada's decision on reducing illicit drug harm.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2006 Sep; 6(9):537. PubMed ID: 16931401
    [No Abstract]   [Full Text] [Related]  

  • 32. Canada's food and drug regulations.
    CURRAN RE
    Food Drug Cosmet Law Q; 1949 Sep; 4(3):391-411. PubMed ID: 18139337
    [No Abstract]   [Full Text] [Related]  

  • 33. HIV/AIDS and injection drug use: a national (and rational) plan.
    Oscapella E
    Can HIV AIDS Policy Law Newsl; 1997-1998 Winter; 3-4(4-1):19-22. PubMed ID: 11365282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct.
    Lim RR
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):933-41. PubMed ID: 17290483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cannabis prohibition harms Canada's youth.
    Elrod MM
    CMAJ; 2017 Jul; 189(29):E970. PubMed ID: 28739850
    [No Abstract]   [Full Text] [Related]  

  • 36. Vietnam moves forward with harm reduction: an assessment of progress.
    Reid G; Higgs P
    Glob Public Health; 2011; 6(2):168-80. PubMed ID: 20155544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canada's drug problem: time to get serious.
    Voth EA
    CMAJ; 1999 Feb; 160(4):477, 479. PubMed ID: 10081460
    [No Abstract]   [Full Text] [Related]  

  • 39. Legal action 'may end search for truth' in Canada's HIV inquiry.
    Spurgeon D
    Nature; 1996 Feb; 379(6565):479. PubMed ID: 8596619
    [No Abstract]   [Full Text] [Related]  

  • 40. The ethical, legal and social context of harm reduction.
    Pauly B; Goldstone I; McCall J; Gold F; Payne S
    Can Nurse; 2007 Oct; 103(8):19-23. PubMed ID: 17990401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.